IMS2186
IMS2186 is an anti-choroidal neovascularization (CNV) agent that inhibits angiogenesis upstream of VEGF. IMS2186 can arrest cancer cell cycle in G2/M phase, thus exerting anti-proliferation and anti-angiogenesis effects. IMS2186 has no intraocular toxicity and reduces the amount of eye leakage and diseased cells[1].
Product Specifications
CAS Number
1031206-36-6
UNSPSC
12352005
Hazard Statement
H410
Target
VEGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/ims2186.html
Purity
99.96
Solubility
DMSO : 66.67 mg/mL (ultrasonic)
Smiles
O=C1/C(COC2=CC=C(C)C=C12)=C/C3=CC=C(OC)C(O)=C3
Molecular Formula
C18H16O4
Molecular Weight
296.32
Precautions
H410
References & Citations
[1]Falkenstein IA, et al. Toxicity and intraocular properties of a novel long-acting anti-proliferative and anti-angiogenic compound IMS2186. Curr Eye Res. 2008 Jul;33 (7) :599-609. |[2]DeNiro M, et al. Reversal of retinal vascular changes associated with ocular neovascularization by small molecules: progress toward identifying molecular targets for therapeutic intervention[J]. VASCULAR, 2011, 15: P17.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K0902104 1.0 µg DNA
GPT sgRNA CRISPR Lentivector (Human) (Target 3)
Sign In for Pricing
View Details Z01LS-1122-LS623 5 Plates
Human PDLIM1 Matched Antibody Pair Set [IV1150/Poly]
Sign In for Pricing
View Details 
APG01557G 0.1mg
Monoclonal ADCY5 Antibody (monoclonal) (M01), Clone: 3E7
Sign In for Pricing
View Details 